Reversing Chemo failure in ovarian cancer with Thomas Zindrick
August 19, 2026
Platinum chemotherapy is the backbone of ovarian cancer treatment. But for far too many patients, it eventually stops working.
In this episode of Power to the Patients, Brandon Li sits down with Thomas Zindrick, CEO and President of Genelux Corporation, to discuss Olvi-Vec, platinum resensitization, and why oncolytic virus therapy could give clinicians a new way to work with existing cancer treatments.
Platinum resistance is one of the hardest questions to solve in clinical oncology, but some answers are beginning to emerge.
For many ovarian cancer patients, platinum-based chemotherapy works well at first. Then resistance begins: the tumor adapts, treatment loses effect, and clinical options narrow.
That is the clinical problem Thomas Zindrick and his team at Genelux Corporation are trying to address with their lead candidate, Olvi-Vec.
In this episode of Power to the Patients, host Brandon Li speaks with Thomas about Genelux's work in oncolytic virus therapy. They discuss why Olvi-Vec is designed to selectively replicate in tumor cells, trigger systemic immune activity, and modulate the tumor microenvironment.
The goal is not to replace platinum chemotherapy, checkpoint inhibitors, or other oncology tools, but rather to make these combinations work harder for patients who have run out of options.
For many ovarian cancer patients, platinum-based chemotherapy works well at first. Then begins the resistance - the tumor adapts, treatment loses effect and options narrow. That is the clinical problem Thomas Zindrick and the team at Genelux Corp are trying to address with Olvi-Vec.
What You’ll Learn:
- Why platinum resensitization is such a high-priority problem in ovarian cancer
- How Olvi-Vec is designed to work as an oncolytic virus therapy
- Why Thomas describes the platform as off-the-shelf personalized medicine
- How thymidine kinase deletion supports selective replication in tumor cells
- Why Genelux sees other oncology agents as collaborators, not competitors
- How immune activation may support tumor microenvironment modulation
- What the STAT1 pathway has to do with platinum resistance
- Why one platinum-refractory patient’s 17-cycle response mattered clinically
- How the immunity paradox shapes oncolytic virus development
- Why manufacturing, cold chain and viral shedding still matter in this modality
- How late-stage data could shape future frontline development
This is a conversation for anyone who’s thinking seriously about how new mechanisms move from late-stage signals into earlier lines of treatment.
About the Guest:
Thomas Zindrick is the CEO and President of Genelux Corporation, a clinical-stage biopharmaceutical company developing oncolytic virus therapies for solid tumors.
He brings more than three decades of life sciences experience, including a background in biology and patent law, alongside executive leadership roles at Amgen and other biotechnology companies
At Genelux, he leads the development of Olvi-Vec, the company's proprietary oncolytic virus candidate being studied in platinum-resistant and platinum-refractory ovarian cancer and other solid tumor settings.
Episode Resources: